The association between clinical characteristics and HIV-infection in very young infants

HIV Treat Bull - 2008 May-June;9(5/6):17

Polly Clayden, HIV i-Base

There are very few descriptions of characteristics of very young HIV-positive and HIV-exposed infants (<60 days). In settings with no access to PCR or CD4% quantification where clinical presumptive diagnosis is often used, these data could guide diagnostic algorithms for infants.

In an oral presentation, Heather Jaspen from the Faculty of Health Science, University of Stellenbosch, Cape Town, South Africa reported findings from an evaluation of the clinical and immunological parameters of HIV-positive infants and clinical characteristics of exposed, uninfected (EU), and unexposed, uninfected (UU) infants aged 4 to 10 weeks.

HIV-positive infants in this study were enrolled from the CHER study (n=540), and EU (n=125) and UU (n=125) infants were from a vaccine study in Cape Town and Soweto.

The median age of all infants was 44 days (range 28 to 78 days).

The investigators found weight below the 10th centile, oral thrush, lymphadenopathy and hepatomegaly to be significantly associated with HIV-positive status in infants in this study (all p<0.001). Nappy rash, was also more likely in infants with HIV (p<0.05).

Anaemia, neutropenia, gastroenteritis and gastric reflux (GERD) were also associated (p<0.005).

When the investigators looked at clinical characteristics and severe immunosupression (≤25%) in the HIV-positive infants only weight (OR 1.6, 95% CI 1.1-2.4) and lower respiratory tract infection (OR 0.3, 95% CI 0.1-0.7) were associated in an age adjusted analysis.

So the study largely focused on the association between clinical characteristics and HIV infection.

After age adjustment, the investigators found weight in the lowest 10th percentile (OR 3.3, 95% CI 1.6-6.6), oral thrush (OR 5.6, 95%CI 3.0 to 10.2), any lymphadenopathy (OR 8.9, 95%CI 3.8 to 29.8), generalized LAD (OR 9.2, 95% CI 2.9-29.8) and nappy rash (OR 2.4, 95% CI 1.5-4.0) were associated with HIV infection.

When the investigators performed a sensitivity analysis including the following symptoms: oral thrush, any LAD, hepatomegaly, splenomegaly, GERD and weight below the 10th percentile, presence of one symptom gave a sensitivity of 49.6% and specificity of 78.4%. Increasing the cut off to two or more symptoms decreased sensitivity but rapidly increased specificity. Two symptoms gave a specificity of 97.6% with 25% sensitivity. Three or four symptoms gave 100% specificity with 10.2% and 5.6% sensitivity for three and four symptoms respectively.

Dr Jaspen remarked that this is at least as good as the IMCI and WHO algorithms for diagnosis in older children. But, she explained, “Many HIV-infected children will still be missed, therefore PCR in resource limited settings is essential.” She added that these findings need to be validated in different populations before an algorithm can be developed.

Comment

A previous small study from the Cote d’Ivoire [Rouet et al. AIDS. 2002 Nov 22;16(17):2303-9] described a mononucleosis-like syndrome, dermatitis, and generalised lymphadenitis as independent factors associated with acute antiretroviral infection in breast fed infants. Generalised lymphadenopathy had a specificity of 96% and a sensitivity of 32%.

The negative and positive predictive values depended on the MTCT rate: the higher the rate of transmission, the higher the PPV but the lower the NPV. Clinical algorithms are no substitute for affordable sensitive and specific tests, when it comes to decision making about starting ARVs.

Ref: Jaspan H, Myer L, Violari A et al. Clinical and immunological characteristics of very young infants with HIV infection: Children with HIV Early Antiretroviral Study. Conf Retroviruses Opportunistic Infect. 2008 Feb 3-6;15: Oral abstract 76.

2008-05-10
IB080905-14

©2008. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2008. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2008. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.